Celldex Therapeutics, Inc. $CLDX Holdings Lifted by Candriam S.C.A.

Candriam S.C.A. increased its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 7.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 518,476 shares of the biopharmaceutical company’s stock after acquiring an additional 37,351 shares during the period. Candriam S.C.A.’s holdings in Celldex Therapeutics were worth $16,865,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AlphaCentric Advisors LLC raised its stake in shares of Celldex Therapeutics by 4.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 13,299 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 515 shares during the period. Alps Advisors Inc. lifted its holdings in shares of Celldex Therapeutics by 31.4% in the third quarter. Alps Advisors Inc. now owns 104,054 shares of the biopharmaceutical company’s stock valued at $3,372,000 after purchasing an additional 24,889 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Celldex Therapeutics in the third quarter valued at about $42,000. State of Wyoming lifted its holdings in shares of Celldex Therapeutics by 347.3% in the third quarter. State of Wyoming now owns 2,943 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Sterling Capital Management LLC boosted its position in shares of Celldex Therapeutics by 355.2% during the third quarter. Sterling Capital Management LLC now owns 2,376 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,854 shares during the period.

Analysts Set New Price Targets

A number of research firms recently issued reports on CLDX. Morgan Stanley increased their price objective on Celldex Therapeutics from $50.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday, September 23rd. Leerink Partners boosted their target price on Celldex Therapeutics from $70.00 to $88.00 and gave the company an “outperform” rating in a research note on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Thursday, October 15th. Canaccord Genuity Group reduced their price target on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Finally, Stifel Nicolaus set a $68.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, September 22nd. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics has an average rating of “Moderate Buy” and an average target price of $63.08.

Celldex Therapeutics Stock Performance

Shares of CLDX stock opened at $29.87 on Monday. Celldex Therapeutics, Inc. has a 1 year low of $22.10 and a 1 year high of $45.14. The firm’s fifty day moving average price is $32.93 and its two-hundred day moving average price is $32.68. The firm has a market capitalization of $2.35 billion, a P/E ratio of -6.95 and a beta of 1.04.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.06. The business had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.72 million. As a group, equities research analysts forecast that Celldex Therapeutics, Inc. will post -4.17 EPS for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells.

The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity.

Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.